Tablets, Lozenges, Or Pills Patents (Class 424/464)
  • Patent number: 10993929
    Abstract: The addition of a salt to an ALA formulation that is dissolved in the mouth unexpectedly significantly reduces the degree of burning or irritation from ALA exposure during administration. This invention is particularly useful for an oral dissolved form of administration due to the extended time of ALA exposure that is possible with such formulations. The salt-inclusive formulations of the invention can increase efficacy of the ALA administration, reduce negative side effects, or both.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: May 4, 2021
    Assignee: Molecular Product Management, LLC
    Inventor: William C. Zolentroff
  • Patent number: 10980751
    Abstract: The invention refers to a pharmaceutical or nutraceutical composition comprising a core a) comprising an active ingredient and a water-insoluble polymer, a coating layer b) above the core a) comprising a salt of an alginic acid, and a coating layer c) above the coating layer b) comprising an anionic (meth)acrylate copolymer polymerized from a (meth)acrylate monomer mixture comprising 5-75% by weight in relation to the total weight of the (meth)acrylate monomer mixture of (meth)acrylate monomers with an anionic group, wherein the amount of the water-insoluble polymer in the core a) is 2 to 20% by weight in relation to the weight of the core a) and the amount of the salt of an alginic acid in the coating layer b) is 5 to 85% by weight in relation to the weight of the core a) and the amount of the anionic (meth)acrylate copolymer in the coating layer c) is 10 to 75% by weight in relation to the weight of the core a) and to the coating layer b).
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: April 20, 2021
    Assignee: Evonik Operations GmbH
    Inventors: Shraddha Joshi, Ashish Guha, Sanjay Lanke, Vinay Jain, Firouz Asgarzadeh, Mitulkumar M Patel
  • Patent number: 10980739
    Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: April 20, 2021
    Assignee: Progenity, Inc.
    Inventors: Mitchell Lawrence Jones, Christopher Loren Wahl, Sharat Singh, Harry Stylli, Allison Luo
  • Patent number: 10966993
    Abstract: An injectable pharmaceutical composition of a sulfonylurea drug and a preparation method thereof were described. The pharmaceutical composition contains a sulfonylurea drug, a cyclodextrin and an additive.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: April 6, 2021
    Assignee: JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD.
    Inventors: Wu Zhong, Chunsheng Gao, Wei Gong, Song Li, Hongyu Chen
  • Patent number: 10898515
    Abstract: The present invention provides compositions, systems, kits, and methods for preparation prior to a colonoscopy or other gastrointestinal procedure. In particular, the present invention provides a colon lavage system comprising an aqueous portion and a solid portion.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: January 26, 2021
    Assignee: DARK CANYON LABORATORIES, LLC
    Inventor: Dale R. Bachwich
  • Patent number: 10888555
    Abstract: The present invention relates to a new pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or related compounds for beneficially influencing the intestinal microbiota and blood lipid levels. In certain embodiments, the pharmaceutical composition is partially or entirely released into the lower small intestine and/or large intestine.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: January 12, 2021
    Assignee: CONARIS RESEARCH INSTITUTE AG
    Inventors: Georg Wätzig, Dirk Seegert
  • Patent number: 10888517
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: January 12, 2021
    Assignee: Rani Therapeutics, LLC
    Inventor: Mir Imran
  • Patent number: 10881610
    Abstract: An orally disintegrating tablet is disclosed possessing both advantageous hardness and disintegrability. The orally disintegrating tablet is (a) a compression molding product of a mixture comprising: a pharmaceutically active ingredient-containing composition selected from a group consisting of a pharmaceutically active ingredient-containing powder and pharmaceutically active ingredient-containing granules; rapidly disintegrating granules; and a lubricant, (b) wherein the rapidly disintegrating granules comprise a sugar and/or a sugar alcohol, and one or more organic and/or inorganic, hydrophilic and water-insoluble additives.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: January 5, 2021
    Assignee: TOWA PHARMACEUTICAL CO., LTD.
    Inventors: Tomoaki Okushima, Keigo Nakamura, Yutaka Okuda
  • Patent number: 10869877
    Abstract: The disclosure provides controlled release compositions comprising tetracyclines and in some embodiments, doxycycline. The controlled release doxycycline compositions of the invention exhibit a superior dissolution profile and provide reduced side effects such as nausea and irritation.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: December 22, 2020
    Assignee: Mayne Pharma International Pty. Ltd.
    Inventors: Stefan Lukas, Angelo Lepore, Stuart Mudge
  • Patent number: 10864165
    Abstract: An object of the present invention is to provide an orally disintegrating tablet (super-rapid disintegrating tablet) that is heavy and relatively thin, and has an extremely high disintegrability (short disintegration time), and a high tablet hardness, and to provide a simple method for the production of said super-rapid disintegrating tablet without such a complicated process as freeze-drying. This invention relates to an orally disintegrating tablet having a specific surface area of from 1.50 to 4.00 mm2/mg and a weight of from 100 to 300 mg, particularly having a disintegration time in water of 7 seconds or less and an oral disintegration time of 6 seconds or less, a method for the production of said orally disintegrating tablet, and to a disintegrative particulate composition for use in said method.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: December 15, 2020
    Assignee: DAICEL CORPORATION
    Inventors: Tomohito Okabayashi, Atsuhiro Uetomo, Naohiro Hashikawa, Takahiro Hiramura, Tetsuro Morita, Kimiko Ikeda
  • Patent number: 10857097
    Abstract: There is provided a solid dosage form adapted for the release of a biologically active material in the oral cavity wherein the dosage form includes at least one biologically active material, and at least one matrix forming agent, wherein the dosage form substantially dissolves in the oral cavity. A method of producing the same and a kit including the same are also provided.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: December 8, 2020
    Assignee: iX Biopharma Ltd.
    Inventors: Chin Beng Stephen Lim, Vivian Bruce Sunderland, Yip Hang Eddy Lee
  • Patent number: 10857143
    Abstract: An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: December 8, 2020
    Assignee: TRIS PHARMA, INC
    Inventors: Yu-Hsing Tu, Ashok Perumal, Kalyan Kathala
  • Patent number: 10857171
    Abstract: The stable pharmaceutical compositions comprising a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof are disclosed.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: December 8, 2020
    Assignee: WOCKHARDT LIMITED
    Inventors: Mohammad Ajmal Shareef, Mrutunjaya Sahu, Ajaykumar Handa
  • Patent number: 10849891
    Abstract: Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: December 1, 2020
    Assignee: ACADIA Pharmaceuticals Inc.
    Inventors: Ravi Tejwani, Stephen Edward Abele, Emanuel Joseph Vizzotti
  • Patent number: 10842797
    Abstract: Co-crystals comprising at least one nutraceutical compound and at least one co-crystal former with or without impurities. These co-crystals may be included in compositions (optionally also including other components such as pharmaceutically acceptable excipients, other nutritional supplements, etc.) having utility as pharmaceuticals, nutraceuticals, nutritional supplements, and foodstuffs.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: November 24, 2020
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Michael John Zaworotko, Heather Clarke, Arora Kapildev, Padmini Kavuru, Roland Douglas Shytle, Twarita Pujari, Lissette Marshall, Tien Teng Ong
  • Patent number: 10828256
    Abstract: The present invention relates to mannitol granules that are of use for the preparation of tablets by direct compression, which do not require a small amount of lubricant in order to be processed. The present invention also relates to a process for preparing such granules. The present invention also encompasses pulverulent compositions comprising these granules, and also direct compression processes using these pulverulent compositions. Finally, the present invention relates to tablets composed of these pulverulent compositions.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: November 10, 2020
    Assignee: ROQUETT FRERES
    Inventors: Baptiste Boit, Philippe Lefevre
  • Patent number: 10828261
    Abstract: The present disclosure is directed to compositions and methods for the production of a fast dissolving tablets to be used for the delivery of an agent. An agent can be an active pharmaceutical agent or a non-pharmacological agent, which is needed to be delivered by means of a fast dissolving delivery system. The invention solves many industry challenges within the field of fast dissolve technologies, specifically coupling of fast dissolve properties with required physical attributes of strength/robustness required for commercial production and distribution.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: November 10, 2020
    Inventor: Owen Murray
  • Patent number: 10813967
    Abstract: A composition of oily, pungent and odoriferous substances and a process for preparation thereof are described, in particular an extended and sustained release of a stable, free flowing, solid composition of one or more of substances such as capsicum, black pepper, ginger, mustard, cinnamon, garlic, onion, paprika, turmeric and the like, extracts thereof, and/or components thereof, and a process for preparation thereof are described. For example, compositions comprise a substance such as capsicum containing capsaicinoid components, which include for example capsaicin, dihydro-capsaicin, and/or nor-dihydro-capsaicin.
    Type: Grant
    Filed: August 19, 2014
    Date of Patent: October 27, 2020
    Assignee: OmniActive Health Technologies Limited
    Inventors: Jayant Deshpande, Girish Achliya, Pravin Nalawade, Prakash Bhanuse, Swapnil Khamborkar
  • Patent number: 10806685
    Abstract: The present invention relates to oral care compositions and to method of maintaining oral health. The oral care composition of the present invention comprises at least one carbon dioxide source, at least one acid source, at least one abrasive and one or more pharmaceutically acceptable excipients.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: October 20, 2020
    Assignee: RUBICON RESEARCH PRIVATE LIMITED
    Inventors: Pratibha Sudhir Pilgaonkar, Maharukh Tehmasp Rustomjee, Anilkumar Surendrakumar Gandhi
  • Patent number: 10786518
    Abstract: The disclosure is directed to methods of treating subjects infected with HIV, once daily, with single unit dosage forms that include darunavir (or a hydrate or solvate thereof), cobicistat, emtricitabine, and a tenofovir prodrug, or salt thereof.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: September 29, 2020
    Assignees: Janssen Sciences Ireland UC, Gilead Sciences, Inc.
    Inventors: Katia Boven, Goedele De Smedt, Regina Driesen, Dominiek Henrist, Greet Kauwenberghs, Sandeep Mathur, Scott McCallister, Roel Mertens, Richard Nettles, Magda Opsomer, William Pyrz, Vahid Zia
  • Patent number: 10716760
    Abstract: Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclose.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: July 21, 2020
    Assignee: Arbor Pharmaceuticals, LLC
    Inventors: Sami Karaborni, Sarina Grace Harris Ma, Chen Mao, Ching Wah Chong, Peter Robert Prinz Freed, Mesut Ciper, Stefanie Krenzlin, David J. Wustrow, Peter A. Virsik
  • Patent number: 10718840
    Abstract: A method for the preparation of a highly polarized nuclear spins containing sample of an organic or inorganic material, containing H or OH groups or adsorbed water molecules. Such highly polarized nuclear spins containing samples can be subjected to nuclear magnetic resonance (NMR) measurement and/or can be thawed and immediately administered to an individual undergoing a magnetic resonance imaging (MRI) scan. The method is based on generating unstable radicals on the surface of the sample in the presence of ionized environment followed by cooling the sample to cryogenic temperatures. A device for carrying out a particular step of said method is also discloses.
    Type: Grant
    Filed: June 26, 2016
    Date of Patent: July 21, 2020
    Assignees: Technion Research & Development Foundation Limited, Yeda Research and Development Co. Ltd.
    Inventors: Aharon Blank, Itai Katz, Akiva Feintuch
  • Patent number: 10709755
    Abstract: The present invention relates to stabilization of a certain benzothia(dia)zepine derivative in a solid formulation containing the same. In the present invention, in a solid formulation containing the benzothia(dia)zepine derivative mentioned above, a combination of polyethylene glycol and polyvinyl alcohol is not blended, or alternatively, in the case of blending polyethylene glycol and polyvinyl alcohol in the solid formulation, the aforementioned derivative is isolated from the combination of polyethylene glycol and polyvinyl alcohol.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: July 14, 2020
    Assignee: Elobix AB
    Inventors: Takahiko Ando, Hirokazu Hagio, Takashi Matsushita, Yusuke Ito
  • Patent number: 10688055
    Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: June 23, 2020
    Assignee: INSPIRION DELIVERY SCIENCES, LLC
    Inventors: Manish S. Shah, Ray J. DiFalco
  • Patent number: 10675379
    Abstract: The present invention relates to biomaterial in the form of dispersion of cellulose nanofibrils with extraordinary shear thinning properties which can be converted into desire 3D shape using 3D Bioprinting technology. In this invention cellulose nanofibril dispersion, is processed through different mechanical, enzymatic and chemical steps to yield dispersion with desired morphological and rheological properties to be used as bioink in 3D Bioprinter. The processes are followed by purification, adjusting of osmolarity of the material and sterilization to yield biomaterial which has cytocompatibility and can be combined with living cells. Cellulose nanofibrils can be produced by microbial process but can also be isolated from plant secondary or primary cell wall, animals such as tunicates, algae and fungi. The present invention describes applications of this novel cellulose nanofibrillar bioink for 3D Bioprinting of tissue and organs with desired architecture.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: June 9, 2020
    Assignee: CELLINK AB
    Inventor: Paul Gatenholm
  • Patent number: 10668679
    Abstract: A process for producing tyres including building a green tyre having two bead structures. Each bead structure includes a bead filler. The bead filler or another rigid component of the green tyre includes a final elastomeric compound produced by the following: feeding elastomeric polymer and reinforcement filler to a first batch mixing device; mixing and dispersing the reinforcement filler in the elastomeric polymer and unloading the obtained elastomeric compound; feeding the obtained elastomeric compound, along with at least 5 phr of reinforcement resin, to a continuous mixing device of intermeshing and co-rotating twin-screw or multi-screw type or of planetary type; mixing the reinforcement resin in the elastomeric compound and unloading the obtained elastomeric compound; and feeding the obtained elastomeric compound along with the components capable of facilitating the cross-linking to a second batch mixing device and mixing to obtain the final elastomeric compound.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: June 2, 2020
    Assignee: PIRELLI TYRE S.P.A.
    Inventors: Elena Prandini, Pierluigi De Cancellis, Alberto Scurati
  • Patent number: 10668073
    Abstract: The present invention relates to a pharmaceutical composition comprising linagliptin or a pharmaceutically acceptable salt thereof as active ingredient, wherein the pharmaceutical composition does not comprise a binder and wherein the pharmaceutical composition is obtained by direct compression.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: June 2, 2020
    Assignee: HEXAL AG
    Inventor: Andreas Krekeler
  • Patent number: 10660957
    Abstract: The present invention provides compositions and methods for treating and preventing an A?-modulated disease. In certain embodiments, the invention provides an inhibitor of Fyn tyrosine kinase, and methods of using the same. In certain embodiments, the inhibitor of the invention inhibits A? oligomer induced signaling and reduces or halts the progression of Alzheimer's Disease.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: May 26, 2020
    Assignee: Yale University
    Inventor: Stephen M. Strittmatter
  • Patent number: 10653629
    Abstract: The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: May 19, 2020
    Assignee: Amorsa Therapeutics, Inc.
    Inventors: Alex Nivorozhkin, Nelson Landrau
  • Patent number: 10632074
    Abstract: The present invention provides a composite granulated product that is optimal for allowing a tablet, preferably an orally disintegrating tablet (OD tablet) to be excellent in disintegrability and have proper hardness. The composite granulated product includes a sugar or a sugar alcohol, a swelling binder, a disintegrating agent, and a highly absorbent excipient.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: April 28, 2020
    Assignee: DAIDO CHEMICAL CORPORATION
    Inventors: Shunji Uramatsu, Toshinobu Uemura, Masakazu Morizane, Toshio Shimamoto
  • Patent number: 10617660
    Abstract: Compositions (e.g., pharmaceutical compositions or nutraceutical compositions) comprising a benzoate compound and an excipient, wherein the excipient is tannic acid, and uses thereof for treating central nervous system disorders.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: April 14, 2020
    Assignee: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Ching-Hsun Huang, Ching-Cheng Wang, Tien-Lan Hsieh
  • Patent number: 10603284
    Abstract: The present invention relates to the field of coating pharmaceutical substrates. In particular, the invention relates to methods of coating of pharmaceutical substances, pharmaceutical ingredients or a blend of them. The invention also provides a method of making a pharmaceutical formulation which may be processed into a pharmaceutical dosage form, which utilizes solid pharmaceutical particles and a pharmaceutical formulation obtained by the method. The methods of the invention utilize atomic layer deposition technology. The novel methods allow difficult, moisture sensitive and electrically charged pharmaceutical substrates to be easily processable.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: March 31, 2020
    Assignee: Applied Materials, Inc.
    Inventors: Pekka Hoppu, Tommi Kaariainen, Marja-Leena Kaariainen, Aimo Turunen
  • Patent number: 10568856
    Abstract: Compositions are disclosed for improved sleep quality and quantity including ingredients for both immediate release and controlled release. The invention provides improved supplemental compositions, and methods for administering same to a user, for enhancing the onset, quality, and duration of sleep in humans and animals. The supplemental composition may contain a combination of ingredients in proportions calculated to relieve stress, promote relaxation, and enhance sleep, including at least the following ingredients: L-Theanine, Skullcap Herb (Scutellaria lateriflora L.), Rhodiola (Rhodiola rosea L.), and Chamomile Flower (Matricaria Recutita). In addition, the supplemental composition may include the secondary ingredient Melatonin. The selection and amounts of the ingredients of the supplemental composition promote sleep onset, quality, and duration and may be provided for consumption at least one time daily, e.g., prior to sleep.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: February 25, 2020
    Inventors: John Doherty, Soring Popa, Dore Miller, Marc Bellemore
  • Patent number: 10526358
    Abstract: The invention relates to the preparation and characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid. The invention also relates to the use of the novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid in pharmaceutical compositions in drug delivery systems for humans. The invention further relates to the use of the novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid or the pharmaceutical compositions thereof to treat and/or prevent a disease state associated with osteoporosis, tumor induced hypercalcemia (TIH), cancer-induced bone metastasis, Paget's disease or for adjuvant or neoadjuvant therapies.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: January 7, 2020
    Assignee: THAR PHARMA, LLC
    Inventors: Mazen Hanna, Ning Shan, David R. Weyna, Miranda L. Cheney
  • Patent number: 10517846
    Abstract: The present application relates to pharmaceutical compositions comprising retinoic acid or its derivatives such as isotretinoin and processes for preparing thereof. It also provides methods for treating acne by administering such pharmaceutical composition to a patient in need thereof.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: December 31, 2019
    Assignee: DR. REDDY'S LABORATORIES LTD.
    Inventors: Yogesh Bapurao Pawar, Kailas Khomane, Saurabh Srivastava, Bijay Kumar Padhi, Rajeev Singh Raghuvanshi
  • Patent number: 10517834
    Abstract: The present disclosure is directed to compositions and methods for the production of a fast dissolving tablets to be used for the delivery of an agent. An agent can be an active pharmaceutical agent or a non-pharmacological agent, which is needed to be delivered by means of a fast dissolving delivery system. The invention solves many industry challenges within the field of fast dissolve technologies, specifically coupling of fast dissolve properties with required physical attributes of strength/robustness required for commercial production and distribution.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: December 31, 2019
    Inventor: Owen Murray
  • Patent number: 10507203
    Abstract: An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: December 17, 2019
    Assignee: TRIS PHARMA, INC
    Inventors: Yu-Hsing Tu, Ashok Perumal, Kalyan Kathala
  • Patent number: 10493096
    Abstract: The invention relates to an oral formulation for targeted delivery of cholestyramine to the colon, comprising a plurality of cholestyramine pellets that are coated with a colon release coating. The invention also relates to the use of this formulation in the treatment of bile acid malabsorption.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: December 3, 2019
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Nils Ove Gustafsson, Nils-Olof Lindberg, Jessica Elversson
  • Patent number: 10478396
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: November 19, 2019
    Assignee: Rani Therapeutics, LLC
    Inventor: Mir Imran
  • Patent number: 10478420
    Abstract: The present invention relates to solid oral formulations comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1?-biphenyl-4-yl)carbonyl]pyrrolidin-3-one-O-methyloxime, and/or an active metabolite thereof, and the use of said formulations in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea and embryo implantation failure due to uterine contractions. The present invention is furthermore related to processes for their preparation.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: November 19, 2019
    Assignee: ObsEva S.A.
    Inventors: Andre Chollet, Oliver Pohl
  • Patent number: 10471071
    Abstract: The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: November 12, 2019
    Assignee: Adare Pharmaceuticals, Inc.
    Inventors: Michael A. Gosselin, Jin-Wang Lai, Gopi M. Venkatesh
  • Patent number: 10456393
    Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: October 29, 2019
    Assignee: Persion Pharmaceuticals LLC
    Inventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
  • Patent number: 10440983
    Abstract: The invention relates to a microcapsule comprising at least one active substance selected from lutein and lutein esters embedded in a matrix comprising fish gelatine and optionally one or more other matrix components, wherein the content of said at least one active substance calculated as free lutein is from 0.5 to 25% of total weight of the microcapsule, and which microcapsule does not comprise any added emulsifier. The invention further relates to a process of preparing the microcapsule as well as uses and products comprising the microcapsule.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: October 15, 2019
    Assignee: BASF SE
    Inventors: Nina Musaeus, Inge-Lise Krylbo
  • Patent number: 10426838
    Abstract: A composite particle comprising from 50 to 80 parts by mass of cellulose, from 10 to 40 parts by mass of an inorganic compound and from 4 to 11 parts by mass of hydroxypropyl cellulose based on 100 parts by mass of a total of contents of the cellulose, the inorganic compound and the hydroxypropyl cellulose.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: October 1, 2019
    Assignee: ASAHI KASEI KABUSHIKI KAISHA
    Inventors: Yosuke Honda, Kazuhiro Obae, Hanayo Kodama
  • Patent number: 10426732
    Abstract: An object of the present invention is to provide an orally disintegrating tablet (ultrafast-disintegrating tablet) having an extremely high disintegrability (short disintegration time), and a high tablet hardness, and to provide a simple method for the production of said ultrafast-disintegrating tablet without such a complicated process as freeze-drying. This invention relates to an orally disintegrating tablet having a specific surface area of from 1.50 to 2.50 mm2/mg and a weight of from 10 to 50 mg, particularly having a disintegration time in water of 7 seconds or less and an oral disintegration time of 5 seconds or less, a method for the production of said orally disintegrating tablet, and to a disintegrative particulate composition for use in said method.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: October 1, 2019
    Assignee: DAICEL CORPORATION
    Inventors: Naohiro Hashikawa, Tomohito Okabayashi, Yoshihisa Takigawa, Atsuhiro Uetomo
  • Patent number: 10413514
    Abstract: Disclosed is a controlled-release solid preparation, which consists of an internal core and a coating layer, wherein part of the surface of the internal core is not covered with the coating, and is exposed to the surface of the solid preparation. Since the medicament just releases at the exposed part, the aim of controlled release can be achieved by controlling this exposed surface area.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: September 17, 2019
    Assignee: OVERSEAS PHARMACEUTICALS, LTD.
    Inventor: Xiaoguang Wen
  • Patent number: 10391094
    Abstract: Provided herein are compositions and methods for treating myelofibrosis in a subject. The methods comprise administering to the subject an effective amount of compound which is which is N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino]benzenesulfonamide or a pharmaceutical salt thereof or a hydrate thereof.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: August 27, 2019
    Assignee: Impact Biomedicines, Inc.
    Inventors: Arvind Jayan, Janice Cacace
  • Patent number: 10376470
    Abstract: Solid dosage formulations containing a combination of rosuvastatin and ezetimibe, as well as methods of making such solid dosage forms and method of treating patients with fixed combination solid dosage forms of rosuvastatin and ezetimibe are provided here.
    Type: Grant
    Filed: August 27, 2017
    Date of Patent: August 13, 2019
    Assignee: Althera Life Sciences, LLC
    Inventors: Marie Charmaine Dias, Chandir Ramani
  • Patent number: 10376521
    Abstract: Co-crystals comprising at least one nutraceutical compound and at least one co-crystal former with or without impurities. These co-crystals may be included in compositions (optionally also including other components such as pharmaceutically acceptable excipients, other nutritional supplements, etc.) having utility as pharmaceuticals, nutraceuticals, nutritional supplements, and foodstuffs.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: August 13, 2019
    Assignee: University of South Florida
    Inventors: Michael John Zaworotko, Heather Clarke, Arora Kapildev, Padmini Kavuru, Roland Douglas Shytle, Twarita Pujari, Lissette Marshall, Tien Teng Ong
  • Patent number: 10376483
    Abstract: A method of delivering a daily dose of hydroxycitric acid in the form of a salt as a single bolus that is as effective or more so than the same amount of active delivered via two or three administrations (b.i.d. or t.i.d.) using current delivery modalities. The method reduces the rate of occurrence of common adverse events with hydroxycitric acid salts, and reduces the occurrence of reverse effects on diets high in fat and/or alcohol. The method improves the uptake of the active compound thereby reducing the dose required.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: August 13, 2019
    Assignee: Glykon Technologies Group, LLC
    Inventors: Dallas L. Clouatre, Daniel E. Clouatre, Brad J. Douglass